<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862680</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0853</org_study_id>
    <secondary_id>NCI-2018-01858</secondary_id>
    <secondary_id>2008-0853</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00862680</nct_id>
  </id_info>
  <brief_title>4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis</brief_title>
  <official_title>4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well 4 dimensional (D) positron emission tomography/computed
      tomography (PET/CT) works in diagnosing participants with lung or colorectal cancer that has
      spread to the liver and lung. Diagnostic procedures, such as PET/CT, may help find and
      diagnose disease and find out how far the disease has spread. But the motions made by
      breathing can reduce the image quality of the scan. Adjusting the scanner to 4D may allow for
      more breathing motion may improve the quality of the PET/CT images.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Study the impact of 4D positron emission tomography/computed tomography (PET/CT) imaging
      on the evaluation and staging of lung and colorectal cancer.

      OUTLINE:

      Participants undergo 4D PET/CT scan over up to 12 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2009</start_date>
  <completion_date type="Actual">April 28, 2019</completion_date>
  <primary_completion_date type="Actual">April 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum lesion standardized uptake value (SUVmax) for gated and ungated positron emission tomography/computed tomography (PET/CT) scans</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Will be compared using a one-sided paired t-test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>two nuclear medicine physicians will assess the impact of the difference in SUVmax on the lesion detectablility and staging of the evaluated patients.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">75</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Liver</condition>
  <condition>Metastatic Malignant Neoplasm in the Lung</condition>
  <condition>Stage IV Colorectal Cancer AJCC v8</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <condition>Stage IVC Colorectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Diagnostic (4D PET/CT)</arm_group_label>
    <description>Participants undergo 4D PET/CT scan over up to 12 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>4-Dimensional Computed Tomography</intervention_name>
    <description>Undergo 4D PET/CT</description>
    <arm_group_label>Diagnostic (4D PET/CT)</arm_group_label>
    <other_name>4D Computed Tomography</other_name>
    <other_name>4DCT</other_name>
    <other_name>Time-Resolved CT Data Acquisition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>4D PET Scan</intervention_name>
    <description>Undergo 4D PET/CT scan</description>
    <arm_group_label>Diagnostic (4D PET/CT)</arm_group_label>
    <other_name>4D Gated PET</other_name>
    <other_name>4D Gated PET Scan</other_name>
    <other_name>4D PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in
             diameter) will be eligible for this study.

          -  Patients with suspected lung cancer with nodules in the lung or liver (1-2 cm in
             diameter) will be eligible for this study.

        Exclusion Criteria:

          -  Patients that cannot tolerate being scanned for an additional 12 minutes with arms
             above their head will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Mawlawi</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

